Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Mepolizumab 300 mg	32
Overall Study	STARTED	Placebo, Followed by Mepolizumab 100 mg	34
Overall Study	Received Intervention	Mepolizumab 300 mg	32
Overall Study	Received Intervention	Placebo, Followed by Mepolizumab 100 mg	33
Overall Study	Completed Month 3	Mepolizumab 300 mg	31
Overall Study	Completed Month 3	Placebo, Followed by Mepolizumab 100 mg	33
Overall Study	Subsequent 3 Months of Treatment (Part 2)	Mepolizumab 300 mg	28
Overall Study	Subsequent 3 Months of Treatment (Part 2)	Placebo, Followed by Mepolizumab 100 mg	28
Overall Study	Completed Month 6	Mepolizumab 300 mg	28
Overall Study	Completed Month 6	Placebo, Followed by Mepolizumab 100 mg	28
Overall Study	COMPLETED	Mepolizumab 300 mg	27
Overall Study	COMPLETED	Placebo, Followed by Mepolizumab 100 mg	26
Overall Study	NOT COMPLETED	Mepolizumab 300 mg	5
Overall Study	NOT COMPLETED	Placebo, Followed by Mepolizumab 100 mg	8

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03656380/flow